FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.
Lim B; Scicchitano A; Beachler C; Gusani N; Sarwani N; Yang Z; Staveley-O'Carroll K; Ashkenazi A; Portera C; El-Deiry WS; Cancer Biology & Therapy, 2013, vol. 14, issue 8, p 711, ISSN 15558576. ISBN 15558576.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef